Cargando…
Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent
The current public health emergency surrounding the COVID-19 pandemic, that is the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in thousands of cases in Australia since 25 January 2020 when the first case was diagnosed. This emerging virus presents par...
Autores principales: | Kaufer, Alexa M., Theis, Torsten, Lau, Katherine A., Gray, Joanna L., Rawlinson, William D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal College of Pathologists of Australasia. Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524674/ https://www.ncbi.nlm.nih.gov/pubmed/33070960 http://dx.doi.org/10.1016/j.pathol.2020.09.006 |
Ejemplares similares
-
Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes
por: Stelzer-Braid, Sacha, et al.
Publicado: (2020) -
Thrombose und COVID-19
por: Tzaneva, Stanislava
Publicado: (2021) -
Clinical evaluation of SARS-CoV-2 point-of-care antibody tests
por: Robosa, Roselle S., et al.
Publicado: (2020) -
Sample pooling is a viable strategy for SARS-CoV-2 detection in low-prevalence settings
por: Chong, Brian S.W., et al.
Publicado: (2020) -
Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection
por: Chua, Kyra Y.L., et al.
Publicado: (2020)